Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

NCT ID: NCT05644184

Last Updated: 2026-01-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 2232 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-03-27
• Study Completion Date: 2026-05-15

Brief Summary

The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for neurovirulence of shed virus (secondary objective) of a novel oral polio type 1 vaccine, nOPV1, as compared to Sabin monovalent type 1 vaccine controls (mOPV1), in healthy young children (192 subjects), infants (720 subjects), and neonates (1320 subjects).

Detailed Description

This single-center trial is the first clinical assessment of nOPV1 in a pediatric population. It will be a 15-arm, randomized, observer-blind, controlled trial, with Sabin monovalent type 1 vaccine (mOPV1) serving as the control. Enrollment in this pediatric study will be staggered into three age-descending cohorts, Cohort 1 composed of 192 healthy young children 1 to less than 5 years of age who have completed their full routine polio immunization series, Cohort 2 composed of 720 healthy infants 6 weeks of age (+6 days) who will receive only one dose of inactivated poliomyelitis vaccine (IPV) on Day 1, and finally Cohort 3, composed of 1320 healthy poliomyelitis unvaccinated neonates (day of birth +3 days). Participants will receive two or three doses of either nOPV1 at dose levels of 10^5.5 CCID50, 10^6.0 CCID50, 10^6.5 CCID50, 10^7.0 CCID50 or 10^7.5 CCID50 or the mOPV control vaccine. The second and third doses of vaccine will be given 28 days following the prior dose. In order to demonstrate the vaccine's ability to reduce fecal shedding following a challenge with the Sabin type 1 strain, the infant cohort will be challenged with mOPV 8 weeks after their last dose of nOPV. Participants will be followed until 28 weeks (young children and neonates) or 32 weeks (infants) after their Day 1 vaccination.

Conditions

Poliomyelitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Group 1: Young Children, nOPV1 10^5.5 CCID50

48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^5.5 CCID50 on Day 1 and Day 29

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Group 3: Young Children, nOPV1 10^6.0 CCID50

48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^6.0 CCID50 on Day 1 and Day 29

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Group 5: Young Children, nOPV1 10^6.5 CCID50

48 young children aged 1 to \<5 years will receive 2 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 1 and Day 29

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Groups 2, 4 and 6: Young Children, mOPV1

48 young children aged 1 to \<5 years will receive 2 doses of mOPV1 at a dose level of ≥ 10\^6.0 CCID50 on Day 1 and Day 29

Group Type: ACTIVE_COMPARATOR

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 7: Infants, nOPV1 10^5.5 CCID50

96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 9: Infants, nOPV1 10^6.0 CCID50

96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 11: Infants, nOPV1 10^6.5 CCID50

48 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 11b: Infants, nOPV1 10^6.5 CCID50

96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 13: Infants, nOPV1 10^7.0 CCID50

96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^7.0 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 15: Infants, nOPV1 10^7.5 CCID50

96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 3 doses of nOPV1 at a dose level of 10\^7.5 CCID50 on Day 29, Day 57 and Day 85, and a challenge dose of mOPV on Day 141.

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Groups 8, 10, 12, 12b, 14, 16: Infants mOPV1

192 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1 then 2 to 3 doses of mOPV1 at a dose level of ≥10\^6.0 CCID50 on Day 29, Day 57, Day 85 (groups 12b, 14 \& 16 only) and a challenge dose of mOPV on Day 113 (groups 8, 10 \& 12) on Day 141 (groups 12b, 14 \& 16)

Group Type: ACTIVE_COMPARATOR

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Group 17: Neonates, nOPV1 10^6.5 CCID50

330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^6.5 CCID50 on Day 1, Day 29 \& Day 57

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Group 19: Neonates, nOPV1 10^7.0 CCID50

330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^7.0 CCID50 on Day 1, Day 29 \& Day 57

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Group 21: Neonates, nOPV1 10^7.5 CCID50

330 neonates (day of birth +3 days) will receive 3 doses of nOPV1 at a dose level of 10\^7.5 CCID50 on Day 1, Day 29 \& Day 57

Group Type: EXPERIMENTAL

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Intervention Type: BIOLOGICAL

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Groups 18, 20 & 22: Neonates, mOPV1

330 neonates (day of birth +3 days) will receive 3 doses of mOPV1 at a dose level of ≥ 10\^6.0 CCID50 on Day 1, Day 29 \& Day 57

Group Type: ACTIVE_COMPARATOR

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Intervention Type: BIOLOGICAL

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Interventions

Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1)

Drop counts of nOPV vaccine will be varied to achieve approximately 10\^5.5, 10\^6.0, 10\^6.5 CCID50 or 10\^7.0, 10\^7.5 dose levels.

Intervention Type: BIOLOGICAL

Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10\^6.0 CCID50 per 0.1 mL (2 drops) dose.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Healthy, as defined by the absence of any clinically significant medical condition or congenital anomaly as determined by medical history, physical examination, and clinical assessment of the investigator

2. Parent(s) or guardian(s) willing and able to provide written informed consent prior to performance of any study-specific procedure

3. Resides in study area and parent understands and is able and willing to adhere to all study visits and procedures (as evidenced by a signed informed consent form [ICF] and assessment by the investigator)

4. Parent agrees for participant to receive all routine infant and childhood immunizations as per the approved protocol-adjusted schedule

1. Male or female child from 1 to less than 5 years of age at the time of initial study vaccination

2. Based on documentation, previously received a 3 or 4 dose primary poliomyelitis immunization series containing OPV (may have also received IPV), with last dose received more than 3 months prior to initial study vaccination

1. Male or female infant expected to be 6 weeks of age (43rd to 49th day of life [with day of birth being the first day of life], inclusive+ 6-day window), at the time of initial study vaccination

2. Prior to study vaccination has received no doses of IPV or OPV, based on no evidence of such vaccination per available documentation.

1. Male or female newborn (1st day of life+ 3-day window, inclusive), at the time of initial study vaccination

2. Prior to study vaccination has received no doses of IPV or OPV or rotavirus vaccine, based on no evidence of such vaccination per available documentation.

Exclusion Criteria

1. For all participants, the presence of anyone under 10 years of age in the participant's household (living in the same house or apartment unit) who does not have complete "age appropriate" vaccination status with respect to poliovirus vaccines at the time of study vaccine administration. For household members younger than 10 years of age, "age appropriate" vaccination is complete series of trivalent Oral Poliovirus Vaccine (tOPV) or at least three doses of bivalent (types 1 and 3) Oral Poliovirus Vaccine (bOPV) plus a booster fractional dose of IPV (fractional dose Inactivated Polio Vaccine; fIPV). Note: A vaccination series of tOPV or at least three doses of bOPV with our without a booster fractional dose of IPV will be considered sufficient.

2. For all participants, having a member of the participant's household (living in the same house or apartment unit) who has received OPV based on the vaccination records in the previous 3 months before study vaccine administration.

3. Any participating children attending day care or pre-school during their participation in the study until one month after their last study vaccine administration.

4. Moderate or severe (grade ≥ 2) acute illness at the time of enrollment/first study vaccination - temporary exclusion. Participant with mild (grade 1) acute illnesses may be enrolled at the discretion of the investigator.

5. Presence of fever on the day of enrollment/first study vaccination (axillary temperature ≥37.5˚C) - (Temporary exclusion for Cohorts 1 and 2)

6. A known allergy, hypersensitivity, or intolerance to any components of the study vaccines, including all macrolide and aminoglycoside antibiotics (e.g., erythromycin and kanamycin)

7. Evidence of a clinically significant congenital or genetic defect as judged by the investigator

8. History of chronic administration (defined as more than 14 days) of immunosuppressant medications, including corticosteroids (> 0.5mg/kg/day of prednisolone (or equivalent)). Topical and inhaler steroids are permitted (unless indicative of a significant chronic illness otherwise excluding the infant/young child)

9. Any self-reported known or suspected immunosuppressive or immunodeficiency condition (including HIV infection) in the participant or household member (living under the same roof/in the same building rather than in the same compound)

10. Receipt of any immune-modifying or immunosuppressant drugs within 6 months prior to the first study vaccine dose or planned use during the study of study participants or a household member

11. Any known or suspected bleeding disorder in the participant that would pose a risk to venipuncture or intramuscular injection

12. Presence of sever malnutrition [weight-for-length/height z-score greater than or equal to -3 SD median (per WHO published growth standards)] - temporary exclusion if marginal and subsequently gains weight.

13. Participation in another investigational product (drug or vaccine) clinical trial within 30 days prior to entry in this study or receipt of any such investigational product other than the study vaccine within 30 days prior tot he first administration of study vaccine, or planned use during the study period.

14. Receipt of transfusion of any blood product or immunoglobulins within 12 months prior to the first administration of study vaccine or planned use during the study period.

15. Parent or participant has any condition that in the opinion of the investigator would increase the participant's health risks in the study participation or would increase the risk of not achieving the study's objectives (e.g., would compromise adherence to protocol requirements or interfere with planned safety and immunogenicity assessments.)

1. Low birth weight (LBW) in newborn participants which is defined as a birth weight of less than 2500g (up to and including 2499b) at the time of birth or by the time of enrolment.

2. Premature birth (less than 37 weeks gestation)

3. From multiple birth (due to increased risk of OPV transmission between siblings)

• Minimum Eligible Age: 0 Days
• Maximum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bill and Melinda Gates Foundation

OTHER

Sponsor Role: collaborator

PT Bio Farma

INDUSTRY

Sponsor Role: collaborator

Centers for Disease Control and Prevention

FED

Sponsor Role: collaborator

DiagnoSearch Life Sciences Pvt. Ltd.

UNKNOWN

Sponsor Role: collaborator

PATH

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

K. Zaman, MBBS, MPH, PhD, FRCP

Role: PRINCIPAL_INVESTIGATOR

International Centre for Diarrhoeal Disease Research, Bangladesh

Locations

International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Dhaka, , Bangladesh

Site Status: RECRUITING

Countries

Bangladesh

Central Contacts

Tushar Tewari, MD

Role: CONTACT

ttewari@path.org

+91 11 4064 0005

Facility Contacts

K. Zaman, MBBS, MPH, PhD, FRCP

Role: primary

kzaman@icddrb.org

+880 2 9827001 10 ext. 3806

Other Identifiers

CVIA 093

Identifier Type: -

Identifier Source: org_study_id